PARP Drugs Help Some Breast Cancer Patients, But They’re No Magic Bullet
For patients with metastatic breast cancer, doctors don’t yet know how to predict long-term responses to this PARP drug.
When A Brilliant Mathematician Dies From Breast Cancer At Age 40
I hope for the future that other brilliant minds will have found and implemented ways to prevent most breast cancers, established accurate methods to detect it early, and developed better treatments, aimed at cures.
More Women Are Living Longer With Metastatic Breast Cancer, But Questions Remain
Metastatic breast cancer patients represent a significant group within the U.S. population who live with a chronic or terminal condition and stand to benefit from new treatments.
Encouraging Results For Ribociclib In Advanced Breast Cancer
Ribociclib is one of several CDK inhibitors being tried in breast cancer and other malignancies.
Raising The Survival Bar, And Access To Information, On Metastatic Cancer
The public has every right to current information on what’s known about survival after a diagnosis of metastatic breast cancer, and for all forms of cancer.
At A Conference On Cancer, Patients Take Notes Like Their Lives Depend On It
Online communities can be terrific. But in person, patients hug one another, and develop trust, bonds that last, hopefully, from one year’s meeting to the next.
Notes From The ‘Die-In,’ A Demonstration For Metastatic Breast Cancer
Die-in for metastatic breast cancer, Washington DC, October 13, 2015 (photo courtesy of Zachary Parker)
Why People With Metastatic Breast Cancer Want To Get Counted
The number of people living with stage 4, metastatic breast cancer is unknown.
Finding Beauty: How Lisa Bonchek Adams Told Her Cancer Story
Lisa wasn’t quiet about life or living with a devastating condition.
Novel Drug Expands Treatment Options For Women With Metastatic Breast Cancer
The FDA’s decision on palbociclib immediately expands treatment options for a large fraction of people living with metastatic breast cancer. What limits enthusiasm is how much this oral drug will cost.
What’s Intriguing And Concerning About Early Results For Keytruda In Breast Cancer
What’s concerning about the preliminary findings is that the median time to response was 18 weeks. For patients to wait four months or longer to see if there’s a benefit seems like a lot; these are women without much time to spare.
Landscape Analysis Reveals How Little Is Known, Or Said, About Metastatic Breast Cancer
Many patients living with metastatic breast cancer need more help than they’re receiving, and many are reluctant to ask.
Perjeta Works In A Form Of Metastatic Breast Cancer: Active In Other Tumors?
Perjeta extends survival in patients with Her2 positive breast cancer. Might drugs targeting Her2 be effective in other malignancies?
October With Metastatic Breast Cancer
Some feel slighted or ignored during awareness month — counter-examples to the common notion of survivorship.
The Outlier’s Message, and Evolutionary Science in Breast Cancer
If a drug helps, keep it going; if it hurts, stop. There are so many algorithms in medicine, and molecular tools, but maybe the bottom line is how the, one, your patient is doing.
Recognizing a Day of National Metastatic Breast Cancer Awareness
Tired of seeing pink? You’re not alone, says Dr. Barron Lerner in a piece on Pink Ribbon Fatigue in the New York Times. While cancer awareness…